• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

byTeddy Guo
March 15, 2023
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma

Click to read this study in The Lancet Oncology. 

Tags: advanced melanomaAtezolizumabBRAF-mutated melanomacobimetinibcutaneous melanomafulminant hepatitishepatic failureliver failuremelanomaskin cancerVemurafenib
Previous Post

Neuropsychological and biomechanical measures dominate assessment of limb pain in athletes

Next Post

Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B

RelatedReports

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
StudyGraphics

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

March 9, 2023
Adding sargramostim to ipilimumab may improve survival in advanced melanoma
Oncology

Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

March 6, 2023
#VisualAbstract: Adjuvant pembrolizumab improves distant  metastasis-free survival in stage IIB-C melanoma
StudyGraphics

#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma

February 13, 2023
#VisualAbstract: Smartphone dispatch of volunteer responders may not increase bystander use of automated external defibrillator in out-of-hospital cardiac arrest
StudyGraphics

#VisualAbstract: Tumor-infiltrating lymphocyte therapy compared to ipilimumab in advanced melanoma

December 22, 2022
Next Post
Study explores effects of daily iron supplementation in 2- to 5-year-olds

Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

Sodium bicarbonate does not prevent declining kidney function in kidney transplant recipients

Nivolumab may be effective in platinum-resistant ovarian cancer

Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Febuxostat may be effective in preventing contrast-induced acute kidney injury
  • Alternative Dose Regimens of Exemestane in Postmenopausal Women with Breast Cancer
  • United States patients receive subcutaneous fluids less frequently than intravenous fluids when compared to Canadian patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options